Literature DB >> 18844065

[The clinical and laboratory features of 263 cases of chronic lymphocytic leukemia].

Zeng-Jun Li1, Lu-Gui Qiu, Tong Wu, Ya-Fei Wang, De-Hui Zou, Yao-Zhong Zhao, Jun-Yuan Qi, Ren-Chi Yang, Lin-Sheng Qian.   

Abstract

OBJECTIVE: To analyze the clinical and laboratory features of chronic lymphocytic leukemia (CLL).
METHODS: Retrospective investigation of 263 patients with CLL in our hospital between Feb. 2000 and Jan. 2007.
RESULTS: The median age was 60 years with male/female ratio of 2.17 : 1. Patients who were asymptomatic at diagnosis (35.4%) had low Rai grades. Fatigue and lymphadenopathy (54.8%) were the most common features at presentation. Infections, connective tissue diseases and secondary tumors frequently occurred in CLL. WBC counts were between (10 - 100) x 10(9)/L, with lymphocytes percentages more than 0.50 in 97.1% patients. Bone marrow was normal- to hyper-cellularity with lymphocytes percentages more than 0.300 in 99.4% patients. Diffuse infiltrations in bone marrow section were found in 72.2% patients. There were lower CD5 (85.1%) and higher CD25 (78.9%) positivities in the present series as compared with that in other reports. Hypogammaglobulinemia, especially hypo-IgM, usually occurred. Chromosome abnormality were rarely found by routine chromosome examination.
CONCLUSIONS: There were some clinical and laboratory characteristics different from that of abroad data. Further exploration of new markers is required for prognosis prediction and treatment choice.

Entities:  

Mesh:

Year:  2008        PMID: 18844065

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  1 in total

1.  Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.

Authors:  Zengjun Li; Fei Li; Shuhua Yi; Zhimin Gu; Zhen Yu; Yan Xu; Xiaoyan Feng; Wei Liu; Dehui Zou; Junyuan Qi; Fenghuang Zhan; Lugui Qiu
Journal:  BMC Cancer       Date:  2015-07-29       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.